Thierry Conroy, MD, of the Institut de Cancérologie de Lorraine, discusses phase III study findings on adjuvant mFOLFIRINOX vs gemcitabine in patients with resected pancreatic ductal adenocarcinomas (Abstract LBA4001).
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of Gustave Roussy, discuss two treatment studies: one testing pegilodecakin with nivolumab or pembrolizumab and the other evaluating an oral CXCR4 inhibitor in combination with axitinib (Abstracts 4509 & 4510).
Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center, and Lisa A. Carey, MD, of the University of North Carolina, discuss the impact of new phase III findings on chemoendocrine treatment vs endocrine treatment alone in hormone receptor–positive, HER2-negative, node-negative breast cancer (Abstract LBA1).
Allen S. Lichter, MD, ASCO’s former Chief Executive Officer, talks with Nancy E. Davidson, MD, of Fred Hutchinson Cancer Research Center, the 2018 recipient of the Visionary Leader Award, named for Dr. Lichter.
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss their perspectives on the top abstracts in bladder cancer presented at the 2018 ASCO Annual Meeting (Abstracts 4507, 4506, 4503, 4504).
David F. McDermott, MD, of Beth Israel Deaconess Medical Center, discusses study findings on pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (Abstract 4500).
